Q-omics provides the consensus-scored CCNJL profile across patient tissues and cancer cell-line models. CCNJL expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CCNJL is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, CCNJL RNA expression shows 15,374 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, COAD, and LSCC as cancer lineages where CCNJL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCNJL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCNJL survival associations across molecular data types. CCNJL RNA expression shows survival associations in the most cancer types (30), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCNJL RNA expression–survival associations across cancer types. High CCNJL expression shows unfavorable associations in KIRP, MESO, UVM, STAD and LGG, but favorable associations in BLCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for CCNJL RNA expression.
This table summarizes CCNJL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CCNJL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCNJL shows lower tumor expression in COAD and LUSC and higher tumor expression in HNSC, LUAD, UCEC and CHOL. The COAD box plot shows higher CCNJL RNA expression in normal versus tumor tissue (log2 FC = −2.211, t-test p < 0.001).
This table shows molecular features associated with CCNJL in patient tissues and cancer cell lines. In patient samples, CCNJL shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CCNJL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
